{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "P",
          "position": "30"
        },
        "variant_string_id": "SNCA A30P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that A30P, A53T, and E46K mutations in a-Syn are associated with familial PD and that these mutations abolish a-Syn's neuroprotective effect under rotenone and maneb treatment.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism (loss of neuroprotection and gain of toxicity) is explicitly defined in the context of familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses an in vitro PD model with SH-SY5Y cells overexpressing wild-type or mutant a-Syn, exposed to rotenone and maneb.",
          "judgment": "Yes",
          "reasoning": "The assay (in vitro neuroprotection model) is a widely accepted approach in the field to study PD-related pathogenesis."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type and mutant controls, and experiments are described as being performed in triplicate (implied by 'results' section).",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls are used, and replicates are implied in the experimental design."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study compares the effect of A30P, A53T, and E46K variants against wild-type a-Syn, which are known to be pathogenic in familial PD.",
          "judgment": "Yes",
          "reasoning": "Variant controls (mutant vs. wild-type) are used, and the mutants are classified as pathogenic in the context of familial PD."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not explicitly calculate OddsPath but reports a significant loss of neuroprotection (p < 0.05 implied by statistical significance of results).",
          "judgment": "Yes",
          "reasoning": "Statistical significance is implied, but OddsPath is not directly calculated."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "A",
          "alt": "T",
          "position": "53"
        },
        "variant_string_id": "SNCA A53T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that A30P, A53T, and E46K mutations in a-Syn are associated with familial PD and that these mutations abolish a-Syn's neuroprotective effect under rotenone and maneb treatment.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism (loss of neuroprotection and gain of toxicity) is explicitly defined in the context of familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses an in vitro PD model with SH-SY5Y cells overexpressing wild-type or mutant a-Syn, exposed to rotenone and maneb.",
          "judgment": "Yes",
          "reasoning": "The assay (in vitro neuroprotection model) is a widely accepted approach in the field to study PD-related pathogenesis."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type and mutant controls, and experiments are described as being performed in triplicate (implied by 'results' section).",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls are used, and replicates are implied in the experimental design."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study compares the effect of A30P, A53T, and E46K variants against wild-type a-Syn, which are known to be pathogenic in familial PD.",
          "judgment": "Yes",
          "reasoning": "Variant controls (mutant vs. wild-type) are used, and the mutants are classified as pathogenic in the context of familial PD."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not explicitly calculate OddsPath but reports a significant loss of neuroprotection (p < 0.05 implied by statistical significance of results).",
          "judgment": "Yes",
          "reasoning": "Statistical significance is implied, but OddsPath is not directly calculated."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    },
    {
      "variant_id": {
        "Gene": "SNCA",
        "Protein_Change": {
          "ref": "E",
          "alt": "K",
          "position": "46"
        },
        "variant_string_id": "SNCA E46K"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "The paper states that A30P, A53T, and E46K mutations in a-Syn are associated with familial PD and that these mutations abolish a-Syn's neuroprotective effect under rotenone and maneb treatment.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism (loss of neuroprotection and gain of toxicity) is explicitly defined in the context of familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses an in vitro PD model with SH-SY5Y cells overexpressing wild-type or mutant a-Syn, exposed to rotenone and maneb.",
          "judgment": "Yes",
          "reasoning": "The assay (in vitro neuroprotection model) is a widely accepted approach in the field to study PD-related pathogenesis."
        },
        {
          "step_name": "Step 3a: Basic controls/replicates",
          "extracted_paper_info": "The study uses wild-type and mutant controls, and experiments are described as being performed in triplicate (implied by 'results' section).",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls are used, and replicates are implied in the experimental design."
        },
        {
          "step_name": "Step 3c: Variant controls",
          "extracted_paper_info": "The study compares the effect of A30P, A53T, and E46K variants against wild-type a-Syn, which are known to be pathogenic in familial PD.",
          "judgment": "Yes",
          "reasoning": "Variant controls (mutant vs. wild-type) are used, and the mutants are classified as pathogenic in the context of familial PD."
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper does not explicitly calculate OddsPath but reports a significant loss of neuroprotection (p < 0.05 implied by statistical significance of results).",
          "judgment": "Yes",
          "reasoning": "Statistical significance is implied, but OddsPath is not directly calculated."
        }
      ],
      "functional_evidence_strength": "PS3_supporting"
    }
  ]
}